© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 10, 2022
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
April 29, 2021
A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
A review of the PSMA-targeted radioligand therapies that are currently in development.
April 20, 2021
Oliver Sartor, MD, reviews clinical data from the TheraP trial looking at the activity of 177Lu-PSMA617 in patients with metastatic castration-resistant prostate cancer.
Key opinion leaders expand on the broad clinical utility of prostate-specific membrane antigen (PSMA) for patients with advanced prostate cancer.
April 13, 2021
Oliver Sartor, MD, and Ulka Vaishampayan, MD, discuss noninvasive imaging with PSMA PET/CT for patients with advanced prostate cancer.